Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anaïs Andrillon

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Biopharmaceutical Statistics|July 27, 2023
Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollmentAnaïs Andrillon, Lucie Biard, Shing M Lee
Statistics in Medicine|October 19, 2022
Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progressionAnaïs Andrillon, Sylvie Chevret, Shing M Lee, et al.
Journal of Biopharmaceutical Statistics|November 23, 2020
Dose-finding design and benchmark for a right censored endpointAnaïs Andrillon, Sylvie Chevret, Shing M Lee, et al.
Clinical Trials (London, England)|April 9, 2024
Dose optimization for cancer treatments with considerations for late-onset toxicitiesLucie Biard, Anaïs Andrillon, Rebecca B Silva, et al.
Ophthalmology|November 18, 2021
Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis NetworkMathilde Leclercq, Anaïs Andrillon, Georgina Maalouf, et al.
American Journal of Ophthalmology|February 16, 2022
Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 PatientsGeorgina Maalouf, Anaïs Andrillon, Mathilde Leclercq, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Biopharmaceutical Statistics|July 27, 2023
Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollmentAnaïs Andrillon, Lucie Biard, Shing M Lee
Statistics in Medicine|October 19, 2022
Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progressionAnaïs Andrillon, Sylvie Chevret, Shing M Lee, et al.
Journal of Biopharmaceutical Statistics|November 23, 2020
Dose-finding design and benchmark for a right censored endpointAnaïs Andrillon, Sylvie Chevret, Shing M Lee, et al.
Clinical Trials (London, England)|April 9, 2024
Dose optimization for cancer treatments with considerations for late-onset toxicitiesLucie Biard, Anaïs Andrillon, Rebecca B Silva, et al.
Ophthalmology|November 18, 2021
Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis NetworkMathilde Leclercq, Anaïs Andrillon, Georgina Maalouf, et al.
American Journal of Ophthalmology|February 16, 2022
Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 PatientsGeorgina Maalouf, Anaïs Andrillon, Mathilde Leclercq, et al.
Pageof 1